Local changes in the type 3 interferons in women with human papillomavirus infection before and after treatment with Inosine pranobex

Cover Page

Cite item

Abstract

 Papillomavirus infection remains one of the main causes of pathological conditions of the female reproductive tract. Innate immunity is one of the first protective mechanisms against this infection, with interferon system being one of its elements. Due to ability of HPV for immune evasion, and lack of uniform clinical recommendations and protocols for management and treatment of women with papillomavirus infection, further studies on probable usage of immunomodulatory drugs are an urgent issue for both fundamental and clinical medicine. Currently, a lot of antiviral and immunomodulatory drugs is used in the treatment of virusassociated diseases of urogenital tract associated with a Th1/Th2 type imbalance. However, the drugs with Inosine pranobex as active substance seem to be the most effective and safe drugs for PVI. The aim of our study was to determine type 3 interferons in the cervical mucus of the women before and after Inosine pranobex therapy.
We have examined 42 patients with papillomavirus infection treated with drugs with the active substance Inosine pranobex. The average age of women was 31±4.1 years. The levels of IL-29 (IFN
λ1) and IL-28 (IFNλ3)
in cervical mucosa were determined using specific reagents from R&D Diagnostics Inc. (USA). The levels of IL-29 (IFN
λ1) were increased in all the groups compared to controls. After treatment, these indexes were
significantly higher, compared with the group before treatment. IL-28 (IFN
λ3) had opposite results to IL-29 (IFNλ1). Thus, in the groups of samples taken before and after therapy, the indexes increased in comparison with the group before treatment, demonstrating the course of recovery towards reference values. The dynamics of studied indexes may be associated with early evaluation period, due to longer duration of immunological changes leading to induction of promoter gene expression, as well as due to insufficient stimulation of these genes. Usage of Inosine pranobex was associated with significantly increased levels of IL-29 (IFNλ1) as soon as a month after therapy. Taking into account genetic homology of type 3 interferons, we may assume that the use of Inosine pranobex drugs in the patients with papillomavirus infection is substantiated, and it may positively affect prognosis of the disease, due to induction of the non-specific immune response. 

About the authors

T. A. Nevezhkina

Pacific State Medical University

Author for correspondence.
Email: www.tanya.ru9292@mail.ru

Assistant Professor, Department of Normal and Pathological Physiology

 690033, Russian Federation, Vladivostok, 100 let Vladivostoku
ave., 62, apt. 20

Phone: 7 (914) 672-89-45 

Russian Federation

A. V. Kostyushko

Pacific State Medical University

Email: fake@neicon.ru

 PhD (Medicine), Associate Professor, Department of Normal and Pathological Physiology

Vladivostok 

Russian Federation

V. E. Krasnikov

Pacific State Medical University

Email: fake@neicon.ru

 PhD (Medicine), Associate Professor, Department of Normal and Pathological Physiology

Vladivostok 

Russian Federation

L. S. Matyushkina

Pacific State Medical University

Email: fake@neicon.ru

PhD (Medicine), Associate Professor, Head, Department of Obstetrics and Gynecology

Vladivostok 

Russian Federation

M. A. Bovdui

Nadezhdinsky Central District Hospital

Email: fake@neicon.ru

 Clinical Obstetrician-gynecologist, Clinical Oncologist, Head, Department of Gynecology

Vladivostok 

Russian Federation

References

  1. Дикке Г.Б., Остроменский В.В. Применение иммуномодуляторов в комплексной терапии инфекций нижнего отдела урогенитального тракта у женщин // Гинекология, 2019. Т. 21, № 1. С. 69-74.
  2. Кныш С.В., Малков В.А., Просекова Е.В., Ковальчук В.К. Особенности интерферонового статуса у пациентов с опоясывающим герпесом // Тихоокеанский медицинский журнал, 2018. №4 (74). С. 34-36.
  3. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Викулов Г.Х., Гомберг М.А., Хрянин А.А. Эффективность и безопасность глюкозаминилмурамилдипептида в лечении заболеваний, ассоциированных с вирусом папилломы человека: систематический обзор // Акушерство, гинекология и репродукция, 2019. Т. 13, № 2. С. 132-154.
  4. Симбирцев А.С. Иммунопатогенез и перспективы иммунотерапии коронавирусной инфекции. ВИЧ-инфекция и иммуносупрессии, 2020. Т. 12, № 4. С. 7-22.
  5. Хрянин А.А., Кнорринг Г.Ю. Остроконечные кондиломы: современные возможности терапии и проблема комплаенса пациентов // РМЖ. Мать и дитя, 2019. Т. 2, № 2. С. 96-101.
  6. Davidson S., McCabe T.M., Crotta S., Gad H.H., Hessel E.M., Beinke S., Hartmann R., Wack A. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol. Med., 2016, Vol. 8, pp. 1099-1112.
  7. Lee S., Baldridge M.T. Interferon-lambda: a potent regulator of intestinal viral infections. Front. Immunol., 2017, Vol. 8, 749. doi: 10.3389/fimmu.2017.00749.
  8. Nelson M., Rubio R., Lazzarin A., Romanova S., Luetkemeyer A., Conway B., Molina J., Xu D., Srinivasan S., Portsmouth S. Safety and efficacy of pegylated interferon lambda, ribavirin, and daclatasvir in HCV and HIVcoinfected patients. J. Interferon Cytokine Res., 2017, Vol. 37, no. 3, pp. 103-111.
  9. Österlund P.I., Pietilä T.E., Veckman V., Kotenko S.V., Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) Genes. J. Immunol., 2007, Vol. 179, no. 6, pp. 3434-3442.
  10. Zheng Y., Li H., Yu J., Zhao H., Wang S.E., Ren X. Interferon-λs: Special immunomodulatory agents and potential therapeutic targets. J. Innate Immun., 2013, Vol. 5, pp. 209-218.
  11. Zhou J., Wang Y., Chang Q., Ma P., Hu Y., Cao X. Type III interferons in viral infection and antiviral immunity. Cell. Physiol. Biochem., 2018, Vol. 51, no. 1, pp. 173-185.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Nevezhkina T.A., Kostyushko A.V., Krasnikov V.E., Matyushkina L.S., Bovdui M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Свидетельство о регистрации СМИ ПИ № 77 - 11525 от 04.01.2002 выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies